25. (Once amended) A vaccine composition comprising at least one antigen and at least one amphipathic adjuvant compound possessing a lipophilic group derived from a sterol linked to a cationic group via a carbamoyl group.

30. (Once amended) The vaccine composition of claim 26, wherein said amphipathic adjuvant compound is selected from the group consisting of cholesteryl-3β-carboxamidoethylenetrimethylammonium iodide, cholesteryl-3β-carboxamidoethylenamine, cholesteryl-3β-oxysuccinamidoethylene-trimethylammonium iodide, 3β-(N-(N′, N′-dimethylaminoethane)carbamoyl)cholesterol, and 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

31. (Once amended) The vaccine composition of claim 30, wherein said amphipathic adjuvant compound is 3β-(N-(N′, N′-dimethylaminoethane)carbamoyl) cholesterol.

32. (Once amended) The vaccine composition of claim 30, wherein said amphipathic adjuvant compound is 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

33. (Once amended) The vaccine composition of claim 25, further comprising [wherein said amphipathic compound further comprises] a neutral lipid.

34. (Once amended) The vaccine composition of claim 33, wherein the proportion of said neutral lipid to said amphipathic adjuvant compound is greater than 20%.

36. (Once amended) The vaccine composition of claim 25, wherein said amphipathic adjuvant compound is dispersed in an aqueous environment in the form of liposomes.

37. (Once amended) The vaccine composition of claim 25, wherein said amphipathic adjuvant compound takes the form of liposomes including at least one antigen.

38. (Twice amended) A method of making the vaccine composition of claim 25, comprising combining said antigen and said amphipathic adjuvant compound linked to a cationic group via a carbamoyl group to form said composition.

43. (Once amended) The method of claim 39, wherein said amphipathic adjuvant compound is selected from the group consisting of cholesteryl-3β-carboxamidoethylenetrimethylammonium iodide, cholesteryl-3β-carboxamidoethylenamine, cholesteryl-3β-oxysuccinamidoethylenetrimethylammonium iodide, 3β-(N- (N′, N′-dimethylaminoethane)carbamoyl)cholesterol, and 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

44. (Once amended) The method of claim 43, wherein said amphipathic adjuvant compound is 3β-(N-(N′, N′-dimethylaminoethane)carbamoyl)cholesterol.

45. (Once amended) The method of claim 43, wherein said amphipathic adjuvant compound is 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

46. (Once amended) The method of claim 38, wherein said amphipathic adjuvant compound is combined with a neutral lipid.

47. (Once amended) The method of claim 46, wherein the proportion of said neutral lipid to said amphipathic adjuvant compound is greater than 20%.

49. (Once amended) The method of claim 38, wherein said amphipathic adjuvant compound is dispersed in an aqueous environment in the form of liposomes.

---

55. (Once amended) The vaccine composition of claim 51, wherein said amphipathic adjuvant compound is selected from the group consisting of cholesteryl-3β-carboxamidoethylenetrimethylammonium iodide, cholesteryl-3β-carboxamidoethylenamine, cholesteryl-3β-oxysuccinamidoethylenetrimethylammonium iodide, 3β-(N-(N′, N′-dimethylaminoethane)-carbamoyl)cholesterol, and 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

56. (Once amended) The vaccine composition of claim 55, wherein said amphipathic adjuvant compound is 3β-(N-(N′, N′-dimethylaminoethane)carbamoyl) cholesterol.

57. (Once amended) The vaccine composition of claim 55, wherein said amphipathic adjuvant compound is 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

58. (Once amended) The vaccine composition of claim 50, further comprising [wherein said amphipathic compound is combined with] a neutral lipid.

59. (Once amended) The vaccine composition of claim 58, wherein the proportion of said neutral lipid to said amphipathic adjuvant compound is greater than 20%.

61. (Once amended) The vaccine composition of claim 50, wherein said amphipathic adjuvant compound is dispersed in an aqueous environment in the form of liposomes.

71. (Once amended) The method of claim 70, wherein said amphipathic adjuvant compound is selected from the group consisting of cholesteryl-3β-carboxamidoethylenetrimethylammonium iodide, cholesteryl-3β-carboxamidoethylenamine, cholesteryl-3β-oxysuccinamidoethylenetrimethylammonium iodide, 3β-(N- (N′, N′-dimethylaminoethane)carbamoyl)cholesterol, and 3β-(N-(polyethylenamine)-carbamoyl)cholesterol.

72. (Once amended) The method of claim 70, wherein said amphipathic adjuvant compound is 3β-(N-(N′, N′-dimethylaminoethane)carbamoyl)cholesterol.

73. (Once amended) The method of claim 70, wherein said amphipathic adjuvant compound is 3β-(N-(polyethylenamine)carbamoyl)cholesterol.

74. (Once amended) A product comprising at least one antigen and one amphipathic adjuvant compound comprising a lipophilic group derived from a sterol linked to a cationic group via carbamoyl group, as a combination product for use simultaneously, separately or staggered over time in vaccination.

75. (Twice amended) A method for inducing an immune response in a mammal, comprising

(a) administering at least one antigen to the mammal; and

(b) further administering at least one amphipathic adjuvant compound comprising a lipophilic group derived from a sterol linked to a polar group via a carbamoyl group.

80. (Twice amended) The method of claim 75, wherein said amphipathic adjuvant compound is administered by the subcutaneous route.

81. (Twice amended) The method of claim 75, wherein said wherein said amphipathic adjuvant compound is administered by the mucosal route.

82. (Twice amended) The method of claim 75, wherein said amphipathic adjuvant compound is administered by the intranasal route.

84. (Once amended) The method of claim 83, wherein said amphipathic adjuvant compound is selected from the group consisting of cholesteryl-3β-carboxamidoethylenetrimethylammonium iodide, cholesteryl-3β-